Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zirconium Zr 89 crefmirlimab berdoxam PET Imaging in Metastatic NSCLC
NCT06863233Phase 1Completed
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Mar 2025
- Primary completion
- Aug 2026
- Modality
- Antibody Fragments, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of zirconium-89 crefmirlimab berdoxam in non-small cell lung cancer (NSCLC), sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoint: Difference between Zirconium Zr 89 crefmirlimab berdoxam PET uptake at pre- vs post-TIL infusion and pre- vs post-ACZ redosing at 2 weeks. Started Mar 2025; status: completed.
02
Drugs
zirconium-89 crefmirlimab berdoxam
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06863233.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06863233.